Production (Stage)
Crinetics Pharmaceuticals, Inc.
CRNX
$31.46
-$0.31-0.98%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -96.77M | -80.60M | -76.83M | -74.06M | -66.93M |
Total Depreciation and Amortization | 925.00K | 788.00K | 770.00K | 753.00K | 474.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 16.93M | 15.44M | 15.39M | 16.28M | 10.91M |
Change in Net Operating Assets | -9.54M | -308.00K | -2.15M | 11.40M | 2.69M |
Cash from Operations | -88.45M | -64.67M | -62.82M | -45.62M | -52.86M |
Capital Expenditure | -1.24M | -1.03M | -528.00K | -955.00K | -1.33M |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -84.72M | -541.06M | 21.13M | -52.69M | 1.64M |
Cash from Investing | -85.96M | -542.09M | 20.60M | -53.64M | 309.00K |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 4.44M | 586.18M | 58.83M | 5.48M | 410.87M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -32.14M | -1.50M | 14.00K | -17.30M |
Cash from Financing | 4.44M | 554.04M | 57.33M | 5.50M | 393.57M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -169.98M | -52.72M | 15.11M | -93.76M | 341.03M |